Privi Speciality Chemicals Ltd Q1 FY26 Results & Concall Highlights: Revenue, Margins & Order Book
Published 14 Jun 2026 | Chemicals & Petrochemicals | Market Cap: ₹14.3K Cr
The company targets a revenue of Rs. The company targets sustained growth with a vision to achieve Rs.
From Privi Speciality Chemicals Ltd's Q1 FY26 earnings-call transcript · updated 23 Aug 2026.
Price
₹3,480
Market Cap
₹14.3K Cr
P/E Ratio
40.7
How does Privi Speciality Chemicals Ltd rank in Chemicals & Petrochemicals?
Compare Privi Speciality Chemicals Ltd against every Chemicals & Petrochemicals company this quarter on revenue, margins and earnings-call signals.
Privi Speciality Chemicals Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest: revenue ₹722 Cr, net profit ₹94 Cr.
Full financials →📊 Revenue & Sales Performance
- →The company targets a revenue of Rs. 5,000 crores and an EBITDA of around Rs. 1,000 crores within the next 3-4 years.
- →Annual growth guidance is about 20%, consistent with past performance.
- →Capacity expansions, including converting plants to continuous production and augmentation, are underway to support growth and meet demand.
- →Several new specialty aroma chemicals have been developed at lab and pilot levels, expected to drive future growth post the current capacity expansion slated for completion by March 2026.
- →The company aims to maintain EBITDA margins around 20-22% over the coming years.
- →Efforts are in progress to reduce net working capital days from about 140 to 120-125 to improve operational efficiency.
- →Overall, sustained strong demand, especially from FMCG sectors and stable contracted business (about 70%), supports optimistic growth prospects.
📈 Profitability & Margins
- →The company targets sustained growth with a vision to achieve Rs. 5,000 crore revenue and Rs. 1,000 crore EBITDA in 3-4 years, implying ~20%+ EBITDA margins. (Page 12)
- →EBITDA margins have shown strength at ~22% currently and are expected to be sustainable going forward. (Page 15)
- →Capacity expansions and process debottlenecking are underway which will support continued volume and margin growth. (Pages 7, 14)
- →New specialty products from by-product streams and innovations at lab & pilot scale will drive future margin expansions and revenue growth. (Pages 13,14)
- →The firm expects gross margins (RMC costs) to stay stable at ~53-57%, with cost savings supporting EBITDA margin expansion. (Page 16)
- →Operational efficiencies like plant automation and continuous processing contribute positively to profitability. (Page 7)
- →The company aims to reduce net working capital days to 120-125 to improve cash flow. (Page 13)
- →Overall, management is confident of maintaining >20% EBITDA margins and 20%+ annual growth over next 3-5 years.
🏗️ Capital Expenditure Plans
- →Total planned CAPEX to achieve the 5,000 crore revenue and 1,000 crore EBITDA vision is around Rs. 1,100 crores over the next few years.
- →The first phase of CAPEX is underway with about Rs. 280-300 crores invested, expected to complete by year-end, enabling 20% growth over the next couple of years.
- →Applications for environment clearances are in process for phases II and III to support further expansion.
- →Additional CAPEX includes Rs. 400 crores (approx.) planned for Privi Fine Sciences, with further investments expected mainly in the Lote plant.
- →Funding for CAPEX will be a mix of internal accruals and debt, with minimal reliance on equity.
- →Strategic focus on new and game-changing renewable route products supporting future growth and margin improvement.
💰 Fundraising & Capital Structure
- →The company plans a significant CAPEX of about Rs. 1,100 crores over the next 2-3 years to support growth and capacity expansion.
- →Fundraising for this CAPEX will primarily be through a mix of internal accruals and bank debt.
- →Equity infusion is currently not favored due to its higher cost; hence, the company prefers debt and internal accruals.
- →There is no explicit mention of a new equity fundraising round in the near future.
- →The company aims to keep leverage at manageable levels and avoid becoming highly leveraged.
📋 Order Book & Pipeline
- →The company has indicated that about 70% of their business for the financial year is already contracted.
- →There is strong ongoing demand for their products, which are essential FMCG items used daily (shower, washing clothes, brushing teeth).
- →They have a sustained demand outlook with no major customer delays expected in the near to medium term.
- →The company emphasizes a stable and positive growth trajectory based on current order backlog.
- →The products cater to large F&F industry customers (top 15 globally), facilitating easier commercialization of new products.
- →Capacity expansions and de-bottlenecking efforts are underway to meet growing demand, suggesting the order book is expected to be robust.
- →Orders are globally diversified, with about 70% exports.
- →No specific quantitative details on exact orderbook size were disclosed in the call.
Key Metrics
Continue your research
What Privi Speci.'s management said in earlier quarters
Others in Chemicals & Petrochemicals this season
- Archean Chemical (Q1 FY26)
Q1 FY26 standalone EBITDA grew 13% YoY to INR 958 million with 33% margin; consolidated net profit stood at INR 401 million. Key concall takeaways from Archean…
- PCBL Chemical Ltd (Q1 FY26)
Plant closures in Europe/North America may open export opportunities, boosting international sales beyond the current 41% mix. Key concall takeaways from PCBL…
- Rain Industries Ltd (Q1 FY26)
Carbon segment capacity utilization is around 68%, with efforts to increase utilization underway. Key concall takeaways from Rain Industries's Q1 FY26 earnings…
- Styrenix Perfor. (Q1 FY26)
Thailand plant utilization is at 50-55% with potential to increase revenue by 70-80% by ramping up capacity and improving product mix. Key concall takeaways…
Frequently Asked Questions
What were Privi Speciality Chemicals Ltd Q1 FY26 results?
The company targets a revenue of Rs. The company targets sustained growth with a vision to achieve Rs.
What is Privi Speciality Chemicals Ltd share price analysis?
Privi Speciality Chemicals Ltd currently shows a neutral. The stock trades at a P/E of 40.7 with a market cap of ₹14,250 Cr. Investors should review the full earnings analysis for detailed insights.
Is Privi Speciality Chemicals Ltd planning capital expenditure?
Total planned CAPEX to achieve the 5,000 crore revenue and 1,000 crore EBITDA vision is around Rs.
Keep Privi Speciality Chemicals Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and concall transcripts. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.